Measuring Social Network Buzz Over Pharma Stocks
The partying in San Francisco is winding down now that the hordes of biopharma execs, Wall Street analysts, venture capitalists and other would-be investors have left the annual JP Morgan Healthcare Conference. But who was able to cut through the noise and register the most social media buzz this year?
The companies that generated the largest amount of noise was not a big pharma, but a big biotech. Celgene (CELG) garnered the most attention after providing strong earnings guidance and positive psoriasis results from trials involving its experimental drug apremilast, according to Semantelli, a healthcare focused big data firm.
The rankings, by the way, are a weighted average of the number of Tweets and shares or likes of news articles in social media, as well as mentions in online news, blogs and forums. Celgene, for instance, wound up with a score of 213 compared with Sanofi (SNY), which ranked the lowest with a score of just seven.
Below Celgene was a pair of diet drugmakers. Arena Pharmaceuticals (ARNA) managed to generate some buzz in response to questions about its Belviq pill and reimbursement issues. And Vivus (VVUS) garnered buzz but not for a good reason. Investors were concerned that the growth rate of new prescriptions has not been meeting expectations.
For more Pharma news, go to Pharmalot.
Ed Silverman, a contributing editor of YCharts, is the founder and editor of Pharmalot. He previously reported on the pharmaceutical industry and other business topics for the Star-Ledger of New Jersey, New York Newsday and Investor’s Business Daily. He can be reached at email@example.com.
Filed under: Company Analysis